La Jolla Pharmaceutical Company Stock Price Up 15.6% Following Analyst Upgrade (LJPC)

Share on StockTwits

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) rose 15.6% during trading on Tuesday after Wedbush raised their price target on the stock from $32.00 to $33.00, Stock Ratings Network reports. The company traded as high as $12.08 and last traded at $11.87, with a volume of 442,601 shares traded. The stock had previously closed at $10.27.

A number of other analysts have also recently weighed in on LJPC. Analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $16.00 to $34.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Separately, analysts at Chardan Capital raised their price target on shares of La Jolla Pharmaceutical Company to $54.00 in a research note on Tuesday, March 11th. They now have a “positive” rating on the stock. Finally, analysts at Chardan Capital initiated coverage on shares of La Jolla Pharmaceutical Company in a research note on Thursday, March 6th. They set a “buy” rating and a $32.00 price target on the stock.

The stock’s 50-day moving average is $10.68 and its 200-day moving average is $8.67. The company’s market cap is $50.739 billion.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.17. Analysts expect that La Jolla Pharmaceutical Company will post $-1.20 EPS for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

KiOR Sees Significant Drop in Short Interest
KiOR Sees Significant Drop in Short Interest
Short Interest in Repros Therapeutics Increases By 37.2%
Short Interest in Repros Therapeutics Increases By 37.2%
Digital Ally Short Interest Up 418.9% in August
Digital Ally Short Interest Up 418.9% in August
Impax Laboratories Short Interest Up 18.6% in August
Impax Laboratories Short Interest Up 18.6% in August
Short Interest in New York Mortgage Trust Expands By 10.9%
Short Interest in New York Mortgage Trust Expands By 10.9%
Consolidated Communications Holdings Sees Significant Growth in Short Interest
Consolidated Communications Holdings Sees Significant Growth in Short Interest


Leave a Reply

 
© 2006-2014 Mideast Time.